FDA panel gives nod to Moderna flu shot

"Breakthrough in Flu Protection: FDA Panel Approves Moderna's mFluSiva Shot In a significant move, the FDA's independent vaccine advisors have given their seal of approval to Moderna's mFluSiva flu shot, with a unanimous 9-0 vote. The decision marks a major breakthrough in the fight against seasonal flu, with the panel determining that the benefits of the vaccine outweigh the risks for individuals aged 50 to 64 and those 65 and older. The mFluSiva shot is designed to provide protection against multiple strains of the flu virus, potentially reducing the risk of hospitalization and severe complications associated with the illness. This development comes as the US continues to grapple with the challenges of flu season, and could have significant implications for public health policy and vaccination strategies."

Presented by Planned Parenthood {beacon} Healthcare Health Care PRESENTED BY The Big Story FDA panel gives nod to Moderna flu shot The FDA’s independent vaccine advisors voted unanimously 9-0 that the benefits outweigh the risks for Moderna’s mFlusiva shot in people ages 50 to 64 as well as 65 and older. The shot is...